Demonstrates improved diagnostic yield in non-metastatic lymphadenopathy, indicating selective application is necessary.
Despite advances in PET/CT, tissue confirmation remains essential for mediastinal lymphadenopathy. EBUS-TBNA is minimally invasive but limited by cytology, particularly in benign disease and lymphoma. Emerging EBUS-guided techniques, notably transbronchial mediastinal cryobiopsy, improve diagnostic yield where tissue architecture is required. The multicenter randomized study¹ strengthens evidence for its added value, while underscoring the need for selective application and standardized, indication-specific trials.
No takes yet. Share an insight, caveat, or question.
Engeli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: